Table 4.
Exposure ( creatinine) | OR (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
All women () | Nulliparous women () | |||||||
Pregnancy | Infertility | Unadjusted | Adjustedc | Pregnancy | Infertility | Unadjusted | Adjustedc | |
OPs | ||||||||
DMP | ||||||||
Continuousa | 1.04 (0.75, 1.44) | 1.03 (0.74, 1.44) | 1.02 (0.72, 1.43) | 0.98 (0.69, 1.38) | ||||
Q1 ()b | 96 | 29 | Reference | Reference | 89 | 27 | Reference | Reference |
Q2 (2.99–6.74)b | 84 | 39 | 0.92 (0.51, 1.64) | 0.94 (0.51, 1.72) | 72 | 36 | 0.90 (0.50, 1.64) | 0.97 (0.52, 1.81) |
Q3 (6.74–16.17)b | 91 | 32 | 1.41 (0.81, 2.46) | 1.60 (0.90, 2.84) | 84 | 28 | 1.48 (0.83, 2.64) | 1.74 (0.96, 3.17) |
Q4 () b | 94 | 31 | 1.07 (0.60, 1.89) | 1.13 (0.63, 2.05) | 89 | 30 | 0.99 (0.55, 1.79) | 1.07 (0.58, 1.98) |
p for trend | 0.710 | 0.483 | 0.706 | 0.415 | ||||
DMTP | ||||||||
Continuousa | 0.81 (0.54, 1.23) | 0.83 (0.54, 1.26) | 0.77 (0.50, 1.19) | 0.79 (0.51, 1.24) | ||||
Q1 ()b | 89 | 34 | Reference | Reference | 77 | 32 | Reference | Reference |
Q2 (1.31–2.85)b | 86 | 38 | 1.28 (0.73, 2.28) | 1.30 (0.72, 2.35) | 82 | 35 | 1.40 (0.76, 2.56) | 1.42 (0.76, 2.66) |
Q3 (2.85–5.92)b | 95 | 29 | 1.29 (0.74, 2.26) | 1.32 (0.74, 2.34) | 91 | 29 | 1.43 (0.79, 2.60) | 1.49 (0.81, 2.77) |
Q4 ()b | 95 | 30 | 0.95 (0.53, 1.70) | 0.91 (0.49, 1.66) | 84 | 25 | 1.07 (0.58, 1.97) | 1.07 (0.57, 2.03) |
p for trend | 0.347 | 0.332 | 0.217 | 0.198 | ||||
DEP | ||||||||
Continuousa | 1.00 (0.56, 1.77) | 0.94 (0.52, 1.68) | 0.98 (0.53, 1.78) | 0.91 (0.49, 1.68) | ||||
Q1 ()b | 90 | 33 | Reference | Reference | 84 | 32 | Reference | Reference |
Q2 (5.86–10.12)b | 92 | 33 | 1.01 (0.58, 1.78) | 1.10 (0.61, 1.97) | 85 | 30 | 1.09 (0.61, 1.95) | 1.21 (0.66, 2.22) |
Q3 (10.12–16.15)b | 91 | 32 | 0.98 (0.56, 1.72) | 1.00 (0.56, 1.77) | 79 | 29 | 1.01 (0.56, 1.82) | 1.04 (0.57, 1.91) |
Q4 () b | 92 | 33 | 1.01 (0.58, 1.79) | 1.02 (0.57, 1.82) | 86 | 30 | 1.05 (0.58, 1.91) | 1.07 (0.58, 1.98) |
p for trend | 0.996 | 0.778 | 0.815 | 0.590 | ||||
DETP | ||||||||
Continuousa | 0.74 (0.41, 1.32) | 0.68 (0.37, 1.26) | 0.72 (0.39, 1.32) | 0.66 (0.35, 1.26) | ||||
Q1 ()b | 91 | 33 | Reference | Reference | 84 | 32 | Reference | Reference |
Q2 (2.14–3.49)b | 90 | 33 | 1.32 (0.73, 2.39) | 1.44 (0.77, 2.66) | 81 | 30 | 1.38 (0.75, 2.55) | 1.52 (0.80, 2.88) |
Q3 (3.49–6.28)b | 91 | 32 | 1.53 (0.85, 2.77) | 1.56 (0.84, 2.87) | 83 | 29 | 1.37 (0.73, 2.56) | 1.40 (0.73, 2.68) |
Q4 ()b | 93 | 33 | 2.07 (1.17, 3.68)* | 2.17 (1.19, 3.93)* | 86 | 30 | 2.11 (1.16, 3.85)* | 2.30 (1.23, 4.30)* |
p for trend | 0.231 | 0.146 | 0.274 | 0.180 | ||||
Total DAP | ||||||||
Continuousa | 1.00 (0.55, 1.79) | 0.91 (0.50, 1.66) | 0.96 (0.52, 1.78) | 0.85 (0.45, 1.61) | ||||
Q1 ()b | 94 | 29 | Reference | Reference | 90 | 28 | Reference | Reference |
Q2 (113.42–200.42)b | 83 | 40 | 0.82 (0.46, 1.45) | 0.88 (0.49, 1.59) | 71 | 39 | 0.79 (0.44, 1.42) | 0.90 (0.49, 1.66) |
Q3 (200.42–332.46)b | 96 | 28 | 1.31 (0.76, 2.25) | 1.64 (0.93, 2.91) | 89 | 21 | 1.40 (0.80, 2.45) | 1.89 (1.04, 3.43)* |
Q4 ()b | 92 | 34 | 0.77 (0.43, 1.38) | 0.86 (0.48, 1.56) | 84 | 33 | 0.60 (0.32, 1.12) | 0.68 (0.36, 1.30) |
p for trend | 0.957 | 0.628 | 0.988 | 0.526 | ||||
PYR | ||||||||
3PBA | ||||||||
Continuousa | 0.78 (0.46, 1.32) | 0.81 (0.47, 1.39) | 0.81 (0.47, 1.40) | 0.84 (0.48, 1.46) | ||||
Q1 ()b | 92 | 34 | Reference | Reference | 86 | 28 | Reference | Reference |
Q2 (0.44–0.73)b | 92 | 32 | 1.29 (0.73, 2.30) | 1.22 (0.68, 2.21) | 80 | 30 | 1.22 (0.66, 2.23) | 1.17 (0.63, 2.19) |
Q3 (0.73–1.38)b | 86 | 37 | 1.27 (0.71, 2.27) | 1.26 (0.69, 2.29) | 76 | 37 | 1.40 (0.77, 2.56) | 1.39 (0.75, 2.60) |
Q4 ()b | 95 | 28 | 1.56 (0.88, 2.76) | 1.55 (0.86, 2.79) | 92 | 26 | 1.94 (1.08, 3.50)* | 2.03 (1.10, 3.74)* |
p for trend | 0.306 | 0.403 | 0.287 | 0.349 |
Note: 3PBA, 3-phenoxybenzoic acid; CI, confidence interval; DAP, dialkyl phosphate; DEP, diethylphosphate; DETP, diethylthiophosphate; DMP, dimethylphosphate; DMTP, dimethylthiophosphate; OP, organophosphate; OR, odds ratio; PYR, pyrethroid; Q1–4, quartiles 1–4.
.
Urine concentrations of pesticide metabolites were adjusted for creatinine then .
The cut point of OP and PYR metabolites was determined in a sample size of 496 in the analysis for infertility.
Adjusted for age, prepregnancy BMI, age at menarche, current smoking, education, annual household income, “Have you found that you could not cope with all the things that you had to do?”, and “How often have you been able to control irritations in your life?” in logistic regression models.